Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy

Twaroch, Teresa E; Focke, M.; Civaj, Vera; Weber, Milena; Balic, Nadja; Mari, Adriano; Ferrara, Rosetta; Quirce, Santiago; Spitzauer, Susanne; Swoboda, Ines; Valenta, Rudolf

doi:10.1016/j.jaci.2011.03.011

Cited by 39 publications

(33 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This vaccine design was evaluated with peptides derived from the major allergens from timothy grass pollen (Phl p 1 and Phl p 5) [52, 53•], birch pollen (Bet v 1) [54], olive pollen (Ole e 1) [55], and the Alternaria alternata mould [56] by chemical coupling to keyhole limpet hemocyanin as carrier. Vaccination of mice and rabbits induced specific IgG antibodies that were able to inhibit the binding of IgE of allergic patients to the natural allergens.…”

Section: Treatment Forms Based On Recombinant Allergens and Peptidesmentioning

confidence: 99%

Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy

Marth

Focke‐Tejkl

Lupinek

et al. 2014

Curr Treat Options Allergy

Self Cite

View full text Add to dashboard Cite

Opinion statementAllergic diseases are among the most common health issues worldwide. Specific immunotherapy has remained the only disease-modifying treatment, but it is not effective in all patients and may cause side effects. Over the last 25 years, allergen molecules from most prevalent allergen sources have been isolated and produced as recombinant proteins. Not only are these molecules useful in improved allergy diagnosis, but they also have the potential to revolutionize the treatment of allergic disease by means of immunotherapy. Panels of unmodified recombinant allergens have already been shown to effectively replace natural allergen extracts in therapy. Through genetic engineering, several molecules have been designed with modified immunological properties. Hypoallergens have been produced that have reduced IgE binding capacity but retained T cell reactivity and T cell peptides which stimulate allergen-specific T cells, and these have already been investigated in clinical trials. New vaccines have been recently created with both reduced IgE and T cell reactivity but retained ability to induce protective allergen-specific IgG antibodies. The latter approach works by fusing per se non-IgE reactive peptides derived from IgE binding sites of the allergens to a virus protein, which acts as a carrier and provides the T-cell help necessary for immune stimulation and protective antibody production. In this review, we will highlight the different novel approaches for immunotherapy and will report on prior and ongoing clinical studies.

show abstract

Section: Treatment Forms Based On Recombinant Allergens and Peptidesmentioning

confidence: 99%

Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy

Marth

Focke‐Tejkl

Lupinek

et al. 2014

Curr Treat Options Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Using keyhole limpet hemocyanin-coupled nonallergenic peptides from the major timothy grass pollen allergen Phl p 1, the major birch pollen allergen Bet v 1, and, recently, the major olive pollen allergen Ole e 1, we could induce allergen-specific blocking IgG responses on immunization of animals, suggesting that it might be possible to use this principle for allergy vaccination. 18,19,21 In fact, it was also demonstrated that a nonallergenic peptide from the major house dust mite allergen Der p 1 induced allergen-specific IgG antibodies on vaccination of nonallergic subjects after chemical coupling to the bacteriophage protein Qb. 22 However, chemical coupling of allergen-derived peptides is a cumbersome process that can lead to a variety of reaction products that cannot be well defined.…”

Section: Vaccines Consisting Of Nonallergenic Peptides Fused To Carrimentioning

confidence: 99%

Recombinant allergens: What does the future hold?

Valenta

Niespodziana

Focke-Tejkl

et al. 2011

Journal of Allergy and Clinical Immunology

Self Cite

View full text Add to dashboard Cite

“…Another group had peptides from Ole e 1 that do not bind to IgE and induced IgG in rabbits, which inhibited binding of specific olive tree IgE to Ole e 1 from allergic subjects. 78 Peptides do not activate IgEmediated reactions but induce tolerance in T cells.…”

Section: Novel Delivery Systems and Modified Extractsmentioning

confidence: 99%